KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) EBT Margin (2016 - 2025)

Historic EBT Margin for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to 24.92%.

  • Emergent BioSolutions' EBT Margin fell 235400.0% to 24.92% in Q3 2025 from the same period last year, while for Sep 2025 it was 13.42%, marking a year-over-year increase of 318600.0%. This contributed to the annual value of 13.69% for FY2024, which is 559900.0% up from last year.
  • As of Q3 2025, Emergent BioSolutions' EBT Margin stood at 24.92%, which was down 235400.0% from 11.92% recorded in Q2 2025.
  • Over the past 5 years, Emergent BioSolutions' EBT Margin peaked at 48.47% during Q3 2024, and registered a low of 539.6% during Q2 2024.
  • Its 5-year average for EBT Margin is 40.78%, with a median of 14.18% in 2024.
  • As far as peak fluctuations go, Emergent BioSolutions' EBT Margin crashed by -4655500bps in 2024, and later skyrocketed by 5276800bps in 2025.
  • Quarter analysis of 5 years shows Emergent BioSolutions' EBT Margin stood at 34.97% in 2021, then crashed by -153bps to 18.59% in 2022, then fell by -6bps to 19.7% in 2023, then grew by 28bps to 14.18% in 2024, then soared by 276bps to 24.92% in 2025.
  • Its last three reported values are 24.92% in Q3 2025, 11.92% for Q2 2025, and 41.72% during Q1 2025.